Meeting Banner
Abstract #3905

A pilot study of 18F-PSMA PET/CT or PET/MRI and ultrasound fusion targeted prostate biopsy for intra-prostatic PET-positive lesions

Yachao Liu1, Hongkai Yu2, Jiajin Liu1, Xiaojun Zhang1, Mu Lin3, Holger Schmidt4, Jiangping Gao2, and Baixuan Xu1
1Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing, China, 2Department of Urology Surgery, Chinese PLA General Hospital, Beijing, China, 3MR collaborations, Diagnostic Imaging, Siemens Healthcare, Shanghai, China, 4MR Education, Customer Services, Siemens Healthcare, Erlangen, Germany

The purpose of this study is to evaluate the feasibility and diagnostic performance of 18F-PSMA PET/CT-ultrasound (PET/CT-US) or PET/MRI-ultrasound (PET/MRI-US) fusion targeted biopsy for intra-prostatic PET-positive lesions. 55 candidates were prospectively enrolled for PET/CT-US or PET/MRI-US fusion targeted biopsies at solitary PET-positive lesions. A total of 178 core biopsies were performed on 55 patients. 146 biopsy cores (82.0%, 146/178) from 51 (92.7%, 51/55) patients were positive for prostate cancer; 47 (85.5%, 47/55) were clinically significant prostate cancer. 18F-PSMA PET/CT-US or PET/MRI-US fusion-targeted prostate biopsy are feasible for prostate cancer diagnosis and has high detection rate of clinically significant prostate cancer.

This abstract and the presentation materials are available to members only; a login is required.

Join Here